Physician profile
James E Warren
NPI 1467436451
$1,284.10
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $283 · 2021: $82.50 · 2022: $221 · 2023: $42.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $242.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $160.63 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $118.29 | 2019-2023 | Evusheld |
| Amgen INC. | $117.32 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $92.79 | 2019-2022 | |
| Novo Nordisk INC | $90.48 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $83.12 | 2019-2020 | |
| Amarin Pharma, INC. | $42.89 | 2019-2020 | |
| Abbvie INC. | $35.85 | 2019-2022 | |
| Glaxosmithkline, LLC. | $31.29 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.75 | 2019 | |
| Pfizer INC. | $23.84 | 2019-2022 | |
| Abiomed | $22.91 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $12.76 | 2020 | |
| Dexcom, INC. | $11.97 | 2022 | |
| Medtronic USA, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.